To understand changes in the levels of miRNAs in response to therapy for the same individuals, we recruited a small cohort of late-stage lung cancer patients who were assigned to receive EGFR TKI, and in some cases that progressed on EGFR TKI, with subsequent follow-up radiotherapy or chemotherapy. This evidence concerns the gene EGFR and lung carcinoma.